PCV21 (CAPVAXIVE) Protection and Patient Selection
PCV21 protects against 21 pneumococcal serotypes causing invasive pneumococcal disease (IPD) and pneumonia, including 8 unique serotypes not covered by other pneumococcal vaccines, making it particularly valuable for adults ≥50 years and high-risk individuals aged 19-64 years. 1
What PCV21 Covers
PCV21 provides protection against 21 Streptococcus pneumoniae serotypes: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B 2. This includes:
- 4 serotypes shared with PCV13 (3, 6A, 7F, 19A)
- 7 additional serotypes shared with PCV20 (8, 10A, 11A, 12F, 15C, 22F, 33F)
- 10 novel serotypes unique to PCV21 (9N, 15A, 16F, 17F, 20A, 23A, 23B, 24F, 31, 35B)
Critical caveat: PCV21 does not contain serotype 4, which is present in PCV20 and causes ≥30% of IPD in certain western U.S. populations (Alaska, Colorado, Navajo Nation, New Mexico, Oregon). In these geographic areas, PCV20 should be preferentially selected over PCV21 1.
Who Should Receive PCV21
Age-Based Recommendations
All adults ≥50 years who are pneumococcal vaccine-naïve should receive a single dose of PCV21, PCV20, or PCV15 1, 3. This represents an expansion from the previous ≥65 years threshold.
Risk-Based Recommendations (Ages 19-64 Years)
High-risk conditions requiring PCV21 1:
Immunocompromising conditions (strongest indication):
- Chronic renal failure/nephrotic syndrome
- HIV infection
- Immunodeficiency (congenital or acquired)
- Iatrogenic immunosuppression
- Malignancy (generalized, Hodgkin disease, leukemia, lymphoma, multiple myeloma)
- Solid organ transplant
- Asplenia (congenital or acquired)
- Sickle cell disease/hemoglobinopathies
Anatomic/functional conditions:
- CSF leak
- Cochlear implant
Chronic medical conditions:
- Alcoholism
- Chronic heart disease (CHF, cardiomyopathies)
- Chronic liver disease
- Chronic lung disease (COPD, emphysema, asthma)
- Cigarette smoking
- Diabetes mellitus
Vaccination Algorithm by Prior History
For Vaccine-Naïve Adults (≥50 years or 19-64 with risk factors)
Give PCV21 as a single dose 1
For Previously Vaccinated Adults
If received PPSV23 only:
- Give PCV21 ≥1 year after last PPSV23 dose 1
If received PCV13 only:
- Give PCV21 ≥1 year after PCV13 (≥8 weeks for immunocompromised) 1
If received PCV13 + PPSV23 before age 65:
- Give PCV21 ≥5 years after last pneumococcal vaccine 1
If received PCV13 + PPSV23 at age ≥65:
- Shared clinical decision-making recommended
- If given, administer PCV21 ≥5 years after last dose 1
- Series is complete after PCV21; no additional doses needed 1
If received PCV15:
- Can substitute PCV21 for PPSV23 if PPSV23 unavailable 1
Key Clinical Considerations
Geographic selection: In western U.S. regions with high serotype 4 prevalence (≥30% of IPD), choose PCV20 over PCV21 for broader local coverage 1. In other U.S. regions, PCV21 provides superior coverage of circulating strains 1.
Immunocompromised patients: These individuals may have reduced immune responses to PCV21 2. However, vaccination remains strongly indicated as they face highest disease risk. Consider shorter intervals (8 weeks vs. 1 year) when transitioning from PCV13 1.
Series completion: When PCV21 is used in place of PPSV23, the vaccination series is complete—no additional pneumococcal vaccines are needed 1. This simplifies vaccination schedules compared to PCV15+PPSV23 regimens.
Common adverse reactions (>10%): injection-site pain (41-73%), fatigue (20-36%), headache (11-28%), with most reactions lasting ≤3 days 2. Younger adults (18-49 years) experience higher rates than older adults (≥50 years).
Contraindications: Severe allergic reaction to any vaccine component or diphtheria toxoid 1, 2.
Concomitant vaccination: PCV21 can be given with influenza vaccine, though non-inferiority was not met for serotype 23B when administered concomitantly 2.